Sherpa Healthcare Partners — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
An innovative biopharmaceutical company focused on developing therapies for chronic kidney disease across multiple clinical stages, with a pipeline of eight products covering conditions such as hyperphosphatemia, renal anemia, IgA nephropathy, and diabetic kidney disease.
BiotechDigital HealthHealthtechMedical DevicesShanghai, CN
Co-investorsLAVLilly Asia VenturesQuan Capital3E Bioventures Capital3H Health InvestmentYuanBio Venture Capital
Cerberus Therapeutics is a biotechnology company developing therapeutics based on nanobody technology, a tolerance induction platform, and a KappaLink platform.
BiotechDeep TechHealthtechBoston, US
Novalia Pishesha(Founder)inHidde Ploegh(Founder)Novalia Pishesha, PhD(Co-founder, BoD, SAB)Hidde L. Ploegh, PhD(Co-Founder, SAB)Harvey F. Lodish, PhD(Co-Founder, BoD)Xiaohong Sang(Executive Officer)
Co-investorsBill & Melinda Gates Foundation
EdiGene is a biotechnology company developing genome-editing-based therapies, including allogeneic cell therapies and in vivo RNA base editing platforms, alongside a high-throughput genome editing screening platform.
BiotechDeep TechHealthtech
Co-investorsLAVLilly Asia VenturesWI Harper Group3H Health InvestmentAlwin CapitalBioTrack Capital+2 more
Singleron Biotechnologies develops single-cell and single-nucleus sequencing kits and solutions for transcriptome analysis of biological samples.
BiotechMedical DevicesCologne, DE
Co-investorsARCH Venture PartnersLAVLilly Asia VenturesLake Bleu CapitalMSA CapitalSBCVC
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.